Literature DB >> 3189794

Development of an oxyntomodulin/glicentin C-terminal radioimmunoassay using a "thiol-maleoyl" coupling method for preparing the immunogen.

P Blache1, A Kervran, J Martinez, D Bataille.   

Abstract

Oxyntomodulin (OXM) and glicentin, two peptides processed from proglucagon, both contain the glucagon sequence and a C-terminal basic octapeptide, KRNRNNIA extension. A method to produce antibodies, directed specifically toward the C-terminal extension of these two peptides, was developed; it consisted of the use of thioled bovine serum albumin conjugated with the synthetic N-maleoyl C-terminal octapeptide as the immunogen. Three rabbits (FAN, LEG, and PIP) generated antisera with affinity constants close to 5 X 10(10) M-1. In the radioimmunoassay system, these antisera showed a 100% cross-reactivity with OXM, partially purified rat and human glicentin, and the C-terminal 19-37 OXM fragment. They displayed no cross-reactivity toward the glucagon molecule. The cross-reactivity of C-terminal fragments of OXM demonstrated that the epitope involves the C-terminal hexapeptide and that the two last amino acid residues are essential for the binding. The high-performance liquid chromatography elution profiles of human jejunum or rat intestinal extracts obtained by radioimmunoassay with LEG antiserum showed two major peaks which had the same retention times as OXM and glicentin markers. Thus, the major end products in the human and rat small intestine are OXM and glicentin. In human or rat pancreas, the two main peaks detected were glucagon and the C-terminal hexapeptide of OXM/glicentin. Small amounts of OXM were also found in pancreas, whereas no significant quantities of glicentin could be detected. The "thiol-maleoyl" coupling method described here, and applied to produce C-terminal OXM/glicentin specific antisera, might be of general use to obtain antibodies against a well-defined epitope.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3189794     DOI: 10.1016/0003-2697(88)90172-8

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  5 in total

1.  N-acetyl oxyntomodulin30-37: pharmacokinetics and activity on gastric acid secretion.

Authors:  C Carles-Bonnet; C Jarrousse; H Niel; J Martinez; M Rolland; D Bataille
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-01       Impact factor: 3.000

2.  Immunological and biochemical characterization of processing products from the neurotensin/neuromedin N precursor in the rat medullary thyroid carcinoma 6-23 cell line.

Authors:  J N Bidard; F de Nadai; C Rovere; D Moinier; J Laur; J Martinez; J C Cuber; P Kitabgi
Journal:  Biochem J       Date:  1993-04-01       Impact factor: 3.857

3.  Purification and sequence of rat oxyntomodulin.

Authors:  N L Collie; J H Walsh; H C Wong; J E Shively; M T Davis; T D Lee; J R Reeve
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

Review 4.  Unraveling oxyntomodulin, GLP1's enigmatic brother.

Authors:  Alessandro Pocai
Journal:  J Endocrinol       Date:  2012-09-27       Impact factor: 4.286

5.  Degradation and Stabilization of Peptide Hormones in Human Blood Specimens.

Authors:  Jizu Yi; David Warunek; David Craft
Journal:  PLoS One       Date:  2015-07-29       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.